About Amblyotech
Amblyotech is a Healthcare company based in Atlanta (United States) founded in 2013, and was acquired by Novartis in April 2020. An app-based treatment for Amblyopia is provided through visual games. Amblyotech has raised $1.84 million across 3 funding rounds from investors including Novartis and Jumpstart Foundry. Its focus areas include Life Sciences, Ophthalmology, Medical Devices and Therapy. Its competitors include NovaVision, Sight Science and Envision Solutions; 2 of its 3 listed competitors have raised funding.
Company details
Amblyotech was founded in 2013 in Atlanta, United States, within the health technology sector. An application is offered for treating Amblyopia, an eye disorder affecting vision coordination, using tablet or smartphone devices paired with 3D glasses. Visual stimuli are delivered separately to each eye during attention-based games, encouraging brain adaptation for improved acuity in the affected eye. Conventional methods like patching, atropine drops, or surgery are not required.
- Headquarters Atlanta, United States
- Stage Acquired
- SectorsHealthcare
- Website amblyotech.com
- Social LinkedIn X Facebook
- Acquired by Novartis (Apr 2020)
Funding Insights of Amblyotech
Amblyotech has successfully raised a total of $1.84M across 3 strategic funding rounds. The most recent funding activity was a Seed round of $735.33 thousand completed in January 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.84M
- Total Rounds 3
- Last Round Seed — $735,334
- First Round $1M
(Jun 2015)
- Investors Count 1
All 3 funding rounds of Amblyotech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2020 | $735,334 | Seed | – | – | – |
| May 2016 | $100,000 | Seed | – | – | |
| Jun 2015 | $1M | Seed | – | – | – |
2 investors in total: 2 institutional.
Investors in Amblyotech
Amblyotech has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Novartis and Jumpstart Foundry.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| jsf.co | ||||
R&D focused on manufacturing of drugs for multiple therapeutic areas | 1996 | novartis.com | Basel, Switzerland |
Investor details for Amblyotech
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Amblyotech
4 dated milestones of Amblyotech across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Amblyotech is founded.
- Funding First funding round of $1.0M.
- Funding Latest funding round, Seed, of $735K.
- Exit Acquired by Novartis.
Competitors of Amblyotech
Amblyotech has 3 listed competitors in our database, 2 of them funded. They include NovaVision, Sight Science and Envision Solutions.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| novavision.com | 2003 | Boca Raton, United States | $38M | Non-invasive devices are developed for vision restoration in stroke survivors. | ||
| sightscience.com | 2006 | Shoreview, United States | $7.52M | 204 | Visual rehabilitation for brain-injured patients with field loss is provided. | |
| envisionvrt.com | 2010 | Henrietta, United States | Delivers comprehensive computer-based therapies for vision restoration. |
Detailed competitors of Amblyotech
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Ophthalmology
3 companies that operate in the same segment as Amblyotech (Ophthalmology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Amblyotech
Complete news archive for Amblyotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Amblyotech
Amblyotech was founded in 2013 and raised its 1st funding round 2 years after it was founded.
Amblyotech is headquartered in Atlanta, United States. It is registered at Atlanta, Georgia, United States.
Amblyotech is a funded company, having raised a total of $1.84M across 3 funding rounds to date. The company's 1st funding round was a Seed of $1M, raised on Jun 2015.
Amblyotech was founded in 2013 in Atlanta, United States, within the health technology sector. An application is offered for treating Amblyopia, an eye disorder affecting vision coordination, using tablet or smartphone devices paired with 3D glasses. Visual stimuli are delivered separately to each eye during attention-based games, encouraging brain adaptation for improved acuity in the affected eye. Conventional methods like patching, atropine drops, or surgery are not required.
Amblyotech's top competitors include Sight Science, NovaVision and Envision Solutions.
Amblyotech has 2 investors. Key investors include Novartis, and Jumpstart Foundry.
Yes. Amblyotech was acquired by Novartis in April 2020.